tweetindex

Alzheimer's Drug Discovery Foundation

@TheADDF · New York, NY · joined 26 Feb 2009

The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.

18 423Followers
4 866Following
5 750Posts total
2.5KViews on collected posts

Against accounts of the same size

5 posts from the last 90 days, next to the 10K–100K follower range. ordinary reach for its size, weaker reaction than most.

Median views526this account980median for 10K–100K
Reach, %2.86%this account3.27%median for 10K–100K
Engagement, %0.99%this account2.01%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post5269800.54×
Reach (views ÷ followers)2.86%3.27%0.87×
Engagement rate0.99%2.01%0.49×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6814 Aug
37119 Aug
52620 Aug
30227 Aug
5991 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.29%4 Aug
0.54%19 Aug
1.52%20 Aug
0.99%27 Aug
1.67%1 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 2.01%.

What the audience does

Likes80.8%21 in total
Reposts15.4%4 in total
Bookmarks3.8%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

The ADDF’s Aaron Burstein spoke with @Inc about LM11A-31, an experimental therapy from ADDF-funded PharmatrophiX that may protect synapses and reduce harmful changes linked to both tau and amyloid in Alzheimer’s. https://t.co/FYDHFiguK4 599 views · 8 likes · 2 reposts · 0 replies 01 Sep 2026 · Open on X →
The ADDF’s CEO, Isobel Coleman, has seen firsthand the extraordinary progress in Alzheimer’s research. She shares how the ADDF will carry that progress forward through scientific expertise, strategic investment, and collaboration. https://t.co/VCojaQSTRu https://t.co/trs57iAfHY 302 views · 3 likes · 0 reposts · 0 replies 27 Aug 2026 · Open on X →
The FDA clearance of @C2NDiagnostics' PrecivityAD2 blood test marks another major milestone in the rapid shift toward more accessible and scalable Alzheimer’s diagnostics, moving Alzheimer’s care closer to precision medicine. https://t.co/nsoBdGceDd https://t.co/mBfBAnlCNN 526 views · 7 likes · 1 reposts · 0 replies 20 Aug 2026 · Open on X →
The ADDF's CEO, Isobel Coleman, shares her vision for the ADDF’s next chapter, driving greater impact across Alzheimer’s research while building on its scientific legacy and catalyzing progress in drug development, biomarkers, and prevention. https://t.co/VCojaQSTRu 371 views · 2 likes · 0 reposts · 0 replies 19 Aug 2026 · Open on X →
Tau research is gaining momentum as the field looks beyond amyloid. In @AARP, the ADDF's Interim Chief Science Officer Laura Nisenbaum explains why tau is closely tied to cognitive decline and why it remains an important target in Alzheimer’s. https://t.co/zz0CYRV3nD 681 views · 1 likes · 1 reposts · 0 replies 04 Aug 2026 · Open on X →

Similar accounts